VivoSim Labs, Inc. (VIVS)
0.1577
+0.01
(+8.24%)
USD |
NASDAQ |
Oct 29, 16:00
0.1445
-0.01
(-8.37%)
After-Hours: 06:05
VivoSim Labs Enterprise Value : -0.8503M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | -0.8503M |
| October 28, 2026 | -0.8886M |
| October 27, 2026 | -0.8739M |
| October 26, 2026 | -0.8685M |
| October 23, 2026 | -0.8796M |
| October 22, 2026 | -0.8448M |
| October 21, 2026 | -0.7886M |
| October 20, 2026 | -0.8068M |
| October 19, 2026 | -0.8509M |
| October 16, 2026 | -0.8528M |
| October 15, 2026 | -0.8078M |
| October 14, 2026 | -0.84M |
| October 13, 2026 | -0.7976M |
| October 12, 2026 | -0.7982M |
| October 09, 2026 | -0.7787M |
| October 08, 2026 | -0.788M |
| October 07, 2026 | -0.7423M |
| October 06, 2026 | -0.7091M |
| October 05, 2026 | -0.6947M |
| October 02, 2026 | -0.7266M |
| October 01, 2026 | -0.6912M |
| September 30, 2026 | -0.6768M |
| September 29, 2026 | -0.7072M |
| September 28, 2026 | -0.6506M |
| September 25, 2026 | -0.6385M |
| Date | Value |
|---|---|
| September 24, 2026 | -0.634M |
| September 23, 2026 | -0.6222M |
| September 22, 2026 | -0.6024M |
| September 21, 2026 | -0.5609M |
| September 18, 2026 | -0.6289M |
| September 17, 2026 | -0.5264M |
| September 16, 2026 | -0.5168M |
| September 15, 2026 | -0.4836M |
| September 14, 2026 | -0.4561M |
| September 11, 2026 | -0.4497M |
| September 10, 2026 | -0.3963M |
| September 09, 2026 | -0.4756M |
| September 08, 2026 | -0.4542M |
| September 04, 2026 | -0.4653M |
| September 03, 2026 | -0.4628M |
| September 02, 2026 | -0.4602M |
| September 01, 2026 | -0.4637M |
| August 31, 2026 | -0.4232M |
| August 28, 2026 | -0.4427M |
| August 27, 2026 | -0.4181M |
| August 26, 2026 | -0.4245M |
| August 25, 2026 | -0.4225M |
| August 24, 2026 | -0.4213M |
| August 21, 2026 | -0.4404M |
| August 20, 2026 | -0.4676M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 566.80M |
| Amgen, Inc. | 292.39B |
| Anika Therapeutics, Inc. | 278.45M |
| BioCryst Pharmaceuticals, Inc. | 2.658B |
| Imunon, Inc. | 4.867M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.338M |
| Revenue (Quarterly) | 0.018M |
| Total Expenses (Quarterly) | 1.356M |
| EPS Diluted (Quarterly) | -0.2554 |
| Gross Profit Margin (Quarterly) | -122.2% |
| Profit Margin (Quarterly) | -7.43K% |
| Earnings Yield | -2.84K% |
| Normalized Earnings Yield | -2954.15 |